期刊文献+

力朴素与奈达伯联合先期化疗对晚期卵巢上皮性癌的临床观察 被引量:7

A clinical observation on neoadjuvant chemotherapy for ovary tumor of advanced stage treated with paclitaxel liposome and nedaplatin
下载PDF
导出
摘要 目的观察力朴素与奈达伯联合行新辅助化疗对晚期卵巢上皮性癌近期的疗效及毒副反应。方法晚期卵巢上皮性癌80例,采用力朴素与奈达伯联合化疗方案(力朴素135 mg/m2,奈达伯80 mg/m2-100 mg/m2),全身静脉化疗结合腹腔灌注化疗,3周为一个疗程,于术前完成1-2个疗程治疗后,行体检、影像学检查及手术治疗,从而判断治疗疗效及毒副作用。结果治疗有效率为92.5%(74/80);白细胞下降发生率为50%(40/80),胃肠道反应发生率为77.5%(62/80);所有患者均未因毒副反应中断或退出治疗。结论力朴素与奈达伯联合行先期化疗对晚期卵巢上皮性癌效果较好,毒副反应较轻。 Objective To study the therapeutic effect and side effects of combined therapy with paclitaxel liposome and Nedaplatin on advanced ovary cancer. Methods 80 cases of ovary cancer with advanced stage were studied. A combined chemotherapy of paclitaxel liposome and Nedaplatin were applied. The dose of paclitax- el liposome was 135 mg/m2 with Nedaplatin 80 mg/m2 - 100 mg/m2. The total course of treatment were three weeks,all eases finish at least 1 - 2 course of treatment. Results The bone marrow depression incidence was 50%, Gastrointestinal tract reaction rate was 77.5% No patient exit the therapy because of side effects. Conclusions The combined therapy of paclitaxel liposome and NDP showed good efficacy accompanied by less side effects.
出处 《实用肿瘤学杂志》 CAS 2008年第6期512-513,516,共3页 Practical Oncology Journal
基金 黑龙江省卫生厅基金资助(2005-060)
关键词 卵巢上皮性癌 力朴素 奈达伯 新辅助化疗 Ovary cancer Paclitaxel liposome Nedaplatin Neoadjuvant chemotherapy
  • 相关文献

参考文献6

二级参考文献29

  • 1蔡树模,汤洁,范建玄,翁仲颖,章桂红.紫杉醇治疗难治性卵巢癌和输卵管癌的临床疗效(附30例分析)[J].中华肿瘤杂志,1995,17(2):135-138. 被引量:39
  • 2侯新朴,陶峰,易友云,王文兰.表面带电脂质体载药及对小鼠体内弓形虫的作用[J].药学学报,1989,24(1):53-57. 被引量:14
  • 3于金明 韩俊庆 等.放射肿瘤临床手册[M].海口:南海出版公司,1994.58. 被引量:3
  • 4Yoshioka T, Gamoh M, Shineha R, et al. A new combination chemotherap with cis-diammine-glycolatium (Nedaplatin) and 5- Fu for advanc ed esophageal cancer. [J]. Inter Med, 1999;38(11)844-848 被引量:1
  • 5Straulinger RM, Sharma A, Murray M, et al. Novel Paclitaxel formulations: taxol-containing liposomes[ J ] . J NCI Monographs, 1993,15:69. 被引量:1
  • 6Sharma A, Sharma US, Straulinger RM, et al. Paclitaxel-liposomes for intracavitary therapy of intraperitoneal P388 leukemia[ J]. Cancer Lett, 1996,107:262. 被引量:1
  • 7Sharma A, Mayhew E, Bolcsak L, et al. Activity of paclitaxel liposome formulations against human ovarian tumor xenografts [ J ]. Int J Cancer, 1997,71:103. 被引量:1
  • 8Balasubrumanian SV, Straubinger RM. Taxol - lipid interactions: taxol -dependent effects on the physical properties of model membranes [J].Biochemistry, 1994, 33 (30): 8 941 -8 947. 被引量:1
  • 9Burke TG, Gao X. Stabilization of topotecan in low pH liposomes composed of distearoy phosphatidylcholine [J]. J Pharm Sci, 1994, 83 (7): 967 - 969. 被引量:1
  • 10Abra RM, Bankert RB, Chen F, et al. The next generation of liposome deliv -ery systems: recent experience with tumor - targeted, sterically - stabilized immunoliposomes and active - loading gradients [J]. J Liposome Res, 2002,12(1 -2): 1 -3. 被引量:1

共引文献73

同被引文献80

引证文献7

二级引证文献57

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部